Tag Archives: gild

Gilead Acquires Drug Program For Fatty Liver Disease

Big-cap biotech Gilead Sciences (GILD) agreed Tuesday to acquire a program from small German biotech Phenex Pharmaceuticals aimed at treating liver disease. Gilead agreed to an unspecified upfront payment and milestone payments totaling up to $470 million for Phenex’s Farnesoid X Receptor program. The company press release emphasized that one of the targets of this program is non-alcoholic steatohepatitis (NASH), a common but largely untreated

CVS Picks Gilead Hep C Drugs As Price War Looms

CVS Health (CVS) on Monday said it would select Gilead Sciences’ (GILD) Sovaldi and Harvoni as the exclusive treatments for hepatitis C patients who use some of its benefit plans, the latest development in what could become a price war among hepatitis C drugmakers. The decision, which takes hold Wednesday, comes after Express Scripts’ (ESRX) move last month to dump Gilead’s drugs from its preferred formulary list for genotype 1 hepatitis C

Gilead Sciences Seen Benefiting From Hep C Market

Gilead Sciences (GILD) is well-positioned in the growing hepatitis C drug market vs. rival AbbVie (ABBV), says an analyst in upgrading his Gilead stock rating. Matthew Harrison, an analyst for Morgan Stanley, raised his Gilead rating to overweight from equal weight. He also raised his price target on Gilead stock to 140 from 100. Gilead Sciences stock was up more than 3.5% in afternoon trading in the stock market today, above 97, and is up 30% for